3.58
-0.03 (-0.83%)
| Penutupan Terdahulu | 3.61 |
| Buka | 3.61 |
| Jumlah Dagangan | 303,015 |
| Purata Dagangan (3B) | 1,136,098 |
| Modal Pasaran | 443,480,064 |
| Harga / Jualan (P/S) | 5.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -197.64% |
| Margin Operasi (TTM) | -123.58% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Nisbah Semasa (MRQ) | 4.46 |
| Aliran Tunai Operasi (OCF TTM) | -136.07 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.34 M |
| Pulangan Atas Aset (ROA TTM) | -27.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ADC Therapeutics SA | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.58% |
| % Dimiliki oleh Institusi | 66.89% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Redmile Group, Llc | 30 Sep 2025 | 15,666,731 |
| Prosight Management, Lp | 30 Sep 2025 | 7,472,303 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 1,390,175 |
| Lynx1 Capital Management Lp | 30 Sep 2025 | 1,325,848 |
| Platinum Investment Management Ltd | 30 Sep 2025 | 1,156,721 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |